Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and $535 price target Stay Ahead of the Market: ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

ToolGen, Inc. (KOSDAQ 199800), led by CEO Jong Sang Ryu and recognized as a global leader in genome editing technology, announced today that it has filed a patent infringement lawsuit in the United ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Reshma Kewalramani’s journey to become the first female CEO of a large, public U.S. biotechnology company after immigrating ...